Gastrointestinal Cancer News

Cancer screening recommendations for recipients of solid-organ transplants varied widely based on the transplanted organ and issuing organization, according to the results of a systematic review.

United States military veterans had an increased frequency of hepatocellular carcinoma at autopsy compared with the general population, according to recent findings published in Clinical Gastroenterology and Hepatology.

In a perspective paper published earlier this year in Public Health Research & Practice, Graham A. Colditz, MD, DrPH, highlighted the impact of 40 years’ worth of data generated by the Nurses' Health Study.

Americans of Hmong descent were more likely to undergo screening for colorectal cancer when given information by trained bilingual/bicultural Hmong lay health educators, according to the results of a cluster randomized controlled trial recently published in Cancer.

The size of hepatocellular adenoma tumors shrinks after menopause in women aged older than 50 years, according to recent findings published in Clinical Gastroenterology and Hepatology.

Websites that provide patients with information on colorectal cancer screening vary significantly in terms of quality and readability, according to recent findings published in Clinical Gastroenterology and Hepatology.

BTG International Canada Inc. announced it received approval for its drug-eluding device, the DC Bead LUMI, from Health Canada. The bead is the first commercially available product for patients with hepatocellular carcinoma and colorectal cancer metastasized to the liver.

More than two-thirds of the authors of National Comprehensive Cancer Network clinical practice guidelines reported at least one financial conflict of interest, according to research published in JAMA Oncology.

The WHO’s International Agency for Research on Cancer working group identified an additional eight types of cancer associated with excess body fatness, including multiple myeloma; meningioma; and cancers of the gastric cardia, liver, gallbladder, pancreas, ovary and thyroid.

Several pharmaceutical companies have provided updates this month on phase 2 or phase 3 trials.